Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

Diabetologia

Volumn 60, Issue 11, 2017, Pages 2192-2199

  Simmons, Rebecca K ^a,b,c,d   Griffin, Simon J ^a,d,e   Lauritzen, Torsten ^a   Sandbæk, Annelli ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Aarhus Institute of Advanced Studies   (Denmark)

^d MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cardiovascular disease; General practice; Mortality; Population; Screening; Trial; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DENMARK; DIABETES RISK SCORE QUESTIONNAIRE; DIABETIC PATIENT; ENDOCRINE PANCREAS FUNCTION TEST; FEMALE; FOLLOW UP; GENERAL PRACTICE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SCREENING TEST; AGED; COMPLICATION; CONTROLLED CLINICAL TRIAL; MASS SCREENING; METABOLISM; MORTALITY; PRIMARY HEALTH CARE; PROCEDURES; RISK FACTOR;

ADULT; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 85027852512     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4299-y     Document Type: Article

References (28)

1. Kuo HS, Chang HJ, Chou P, Teng L, Chen TH (1999) A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 28:233–240
2. Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH (2000) Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med 31:396–402
3. Kahn R, Alperin P, Eddy D et al (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365–1374
4. Schuetz CA, Alperin P, Guda S et al (2013) A standardized vascular disease health check in europe: a cost-effectiveness analysis. PLoS One 8:e66454
5. Herman WH, Ye W, Griffin SJ et al (2015) Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 38:1449–1455
6. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S (2007) Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 335:486
7. Adriaanse MC, Snoek FJ (2006) The psychological impact of screening for type 2 diabetes. Diabetes Metab Res Rev 22:20–25
8. Department of Health (2008) Putting prevention first. Vascular checks: risk assessment and management. Department of Health, London
9. Siu AL (2015) Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. preventive services task force recommendation statement. Ann Intern Med 163:861–868
10. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380:1741–1748
11. Simmons RK, Griffin, S.J., Witte, D.R., Borch-Johnsen, K., Lauritzen, T., Sandbæk, A. (2016) Effect of population screening for cardiovascular risk factors and type 2 diabetes on mortality and cardiovascular events among 1,912,392 Danish adults. Diabetologia DOI:10.1007/s00125-017-4323-2
12. Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167
13. Engelgau MM, Narayan KM, Herman WH (2000) Screening for type 2 diabetes. Diabetes Care 23:1563–1580
14. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24(Suppl 3):S6–11
15. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573
16. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733
17. Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003
18. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553
19. Green A, Sortso C, Jensen PB, Emneus M (2015) Validation of the Danish national diabetes register. Clin Epidemiol 7:5–15
20. UNESCO (1997) International Standard Classification of Education. Available from http://www.unesco.org/education/information/nfsunesco/doc/isced_1997.htm. Accessed 20 Apr 2017
21. Huber PJ (1967) The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press, Berkeley, pp 221–233
22. Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815–819
23. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ (2011) How much does screening bring forward the diagnosis of diabetes and reduce complications? 12-year follow-up of the Ely cohort. Diabetologia 55:1651–1659
24. Porta M, Curletto G, Cipullo D et al (2014) Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care 37:1668–1674
25. Danish National Health Service survey (2004). Available from https://www.sst.dk/da/sundhed-og-livsstil/tobak/tal-og-fakta/danskernes-rygevaner/2004. Accessed 20 Apr 2017
26. Safwat S, Ishak RA, Hathout RM, Mortada ND (2017) Statins anticancer targeted delivery systems: re-purposing an old molecule. J Pharm Pharmacol. doi:10.1111/jphp.12707
27. Prasad V, Lenzer J, Newman DH (2016) Why cancer screening has never been shown to “save lives”-and what we can do about it. BMJ 352:h6080
28. Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K (2008) The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51:2187–2196